Is the combination of resmetirom and semaglutide useful for the treatment of metabolic dysfunction-associated steatohepatitis? Commentary

Is the combination of resmetirom and semaglutide useful for the treatment of metabolic dysfunction-associated steatohepatitis?

Targher, Giovanni
Writing – Original Draft Preparation
2026-01-01

Abstract

Is the combination of resmetirom and semaglutide useful for the treatment of metabolic dysfunction-associated steatohepatitis? Commentary
2026
glucagon‐like peptide‐1 receptor agonist
metabolic dysfunction‐associated steatohepatitis
metabolic dysfunction‐associated steatotic liver disease
resmetirom
semaglutide
thyroid hormone receptor‐β agonist
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/1186547
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact